arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

INSMED Inc

INSM
$118.36 ▼ -2.40 (-1.98%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

INSMED Inc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $25.7B
Dividend Yield
Revenue Growth 296.1%
Op. Margin -0.4%
ROIC -0.1%
FCF / Share $-0.44
Trailing P/E
Price / Book 34.1x
FCF Yield
Debt / Equity 0.72
info Valuation on last close. End-of-day price, Sep 23, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$425.49M
↑ +296.1%
Net Income Profit after all expenses
$-13.24M
↑ +95.9%
Operating Margin Operating profit as % of sales
-0.4%
↑ +99.3% 0th
FCF / Share Free cash flow per share
$-0.44
↑ +58.3%
Long-Term Debt Long-term obligations
$546.77M
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
4
Financial Health
32
Cash Quality
51

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 66 quarters